The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

In attempt to keep R&D costs low, the vivarium business model has emerged as a crucial solution for drug developers.

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, ...

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

The investment will be used to improve R&D infrastructure to develop new treatments and implement new technologies to improve ...

The investment of over $6 million will expand LGM Pharma’s Rosenberg, Texas manufacturing facility as part of its Phase I ...

The new drug development corporation Daimbio announced on the 25th that it has completed a series A funding round worth 12 ...

InTandem Capital Partners (“InTandem Capital” or the “Firm”), a healthcare services-focused private equity firm, announced today that it has partnered with ...

Artificial Intelligence is revolutionizing pharmaceuticals, accelerating drug discovery, and optimizing clinical trials. Yet, ...

First-in-human studies anticipated to begin in 2026Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of ...

The return on investment in pharma research and development (R&D) has increased from the previous year, with GLP-1 drugs ...